Trispecific Antibody Therapy Well-Tolerated Among Patients With Relapsed/Refractory Multiple Myeloma
According to first results of a phase 1 dose escalation study among patients with relapsed/refractory multiple myeloma, ISB 2001, a novel BCMA-CD38-CD3-targeting trispecific antibody, was well-tolerated with low-grade CRS and a manageable safety profile at the selected dosage level.
Sustained objective responses were demonstrated among patients with heavily pre-treated R/R MM, with a high ORR of 75% across dose levels.
These results were presented by Hang Quach, MD, FRACP, FRCPA, MBBS, St Vincent's Hospital Melbourne, East Melbourne, Australia, at the 66th ASH Annual Meeting in San Diego, California.
"Dose-escalation continues with no DLT observed thus far,” the authors wrote.
Source:
Quach H, Augustson B, Sia H, et al. First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Dec 7-10, 2024; San Diego, CA. Abstract: 1026
